Imatinib administration in two patients with liver metastases from GIST and severe jaundice

T De Pas; R Danesi; C Catania; G Curigliano; F De Braud; Italia Sarcoma Group

doi:10.1038/sj.bjc.6601282

Imatinib administration in two patients with liver metastases from GIST and severe jaundice

Br J Cancer. 2003 Oct 20;89(8):1403-4. doi: 10.1038/sj.bjc.6601282.

Authors

T De Pas¹, R Danesi, C Catania, G Curigliano, F De Braud; Italia Sarcoma Group

Affiliation

¹ Department of Medical Oncology, European Institute of Oncology, Via Ripamonti, 435, Milano 20141, Italy. [email protected]

Abstract

Imatinib is the only effective and approved systemic therapy for the treatment of patients with advanced gastrointestinal stromal tumours (GISTs). Although metastases from GISTs most commonly involve the liver, yielding hyperbilirubinaemia, very few data on imatinib administration in subjects with jaundice are available. We provide evidence that imatinib tolerability was not adversely affected by jaundice in two patients with advanced GIST.

Publication types

Case Reports

MeSH terms

Adult
Aged
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / pharmacology*
Benzamides
Female
Gastrointestinal Neoplasms / complications
Gastrointestinal Neoplasms / pathology*
Humans
Imatinib Mesylate
Jaundice / etiology*
Liver Neoplasms / complications*
Liver Neoplasms / secondary*
Male
Piperazines / administration & dosage
Piperazines / adverse effects
Piperazines / pharmacology*
Pyrimidines / administration & dosage
Pyrimidines / adverse effects
Pyrimidines / pharmacology*
Stromal Cells / pathology
Treatment Outcome

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate